{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'A detailed treatment log of the destroyed IMP will be established with the Investigator (or the', 'pharmacist) and countersigned by the Investigator and the monitoring team.', '8.8', 'CONCOMITANT MEDICATION', 'A concomitant medication is any treatment received by the patient concomitantly to any IMP(s) or', 'during study participation.', '8.8.1 Prohibited Concomitant Medication', 'The following concomitant treatments are not permitted during the Screening Period or during the', 'Randomized Treatment Period:', 'SCS for diagnoses other than severe exacerbation of asthma and/or high-potency topical', 'steroids within 30 days before Screening Visit 1, during the Screening Period, and/or', 'during the Randomized Treatment Phase of this study. Intra-articular steroids are not', 'allowed to be used in the above mentioned period.', 'IgE therapy (eg, omalizumab) within 130 days prior to Screening Visit 1, or any other', 'biologic therapy/immunosuppressant to treat inflammatory disease or autoimmune disease', 'within 2 months prior to Screening Visit 1.', 'Allergen immunotherapy (except if initiated more than 3 months prior to Visit 1 and dose', 'stable 1 month prior to Visit 1).', 'Intravenous immunoglobulin (IVIG) therapy.', 'Live Attenuated Vaccines: refer to Appendix C. Live (attenuated) vaccines are allowed in', 'the screening period, if taken at least 4 weeks prior to the administration of the first dose', 'of investigational medicinal product (ie, at least 4 weeks prior to baseline visit).', 'In Brazil, for patients in the yellow fever outbreak affected area (see Appendix N).', 'Asthma relievers other than salbutamol/albuterol or levosalbutamol/levalbuterol: their use', 'is not recommended unless in exceptional circumstances during the study period (eg,', 'prescribed by a physician not participating in the study).', 'Exposure to another antibody within a time period prior to Visit 1 that is less than 5 half-', 'lives of the antibody. In case the half-life is not known, then the minimum interval since', 'exposure to the prior investigative antibody is 6 months. The minimum interval since', 'exposure to any other (non-antibody) investigative study medication is 30 days prior to', 'Visit 1.', 'Any investigational treatment or procedure.', '8.8.2 Permitted Concomitant Medication', 'Antihistamines', 'Dermatological, ocular or intranasal corticosteroids (except for high-potency', 'dermatological corticosteroids)', 'Property of the Sanofi Group - strictly confidential', 'Page 57', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'Cytochrome P450 (CYP) enzyme substrates:', 'The impact of dupilumab on CYP enzyme activity has not been studied and the effect of', 'dupilumab on levels of IL-4 and IL-13 has not been fully characterized. However, IL-4', 'was reported to upregulate CYP2E1, 2B6, 3A4 mRNA expression or downregulate', 'CYP1A2 mRNA (5,6). Human peripheral blood mononuclear cells (PBMC) incubated', 'with various Th2 cytokines showed that IL-4 and IL-13 increased mRNA expression of', 'CYP2B6 and CYP3A4 (5). Since the clinical significance of the limited in vitro findings', 'for IL-4 and IL-13 involvement in CYP regulation and the impact of dupilumab on CYP', 'enzymes is not fully understood, during the study treatment and at least up to the end of', 'follow-up, caution should be used for drugs which are metabolized via these CYP', 'isoforms and which have a narrow therapeutic index. This means that close clinical', 'observation and/or laboratory monitoring as applicable are required in order to enable', 'early detection of toxic manifestations or lack of activity/efficacy of these drugs, followed', 'by dose adjustment or their withdrawal if needed (6,7). Some examples of CYP450', 'substrates with narrow therapeutic index are provided in Appendix D.', 'Property of the Sanofi Group - strictly confidential', 'Page 58', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}